These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 29117154

  • 1. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
    Zhou D, Li Z, Bai X.
    Med Sci Monit; 2017 Nov 08; 23():5321-5329. PubMed ID: 29117154
    [Abstract] [Full Text] [Related]

  • 2. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
    Mesa C, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA.
    Cancer Res; 2006 Jul 01; 66(13):6521-9. PubMed ID: 16818623
    [Abstract] [Full Text] [Related]

  • 3. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R.
    Endocr Relat Cancer; 2008 Jun 01; 15(2):511-20. PubMed ID: 18509003
    [Abstract] [Full Text] [Related]

  • 4. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
    Zhao S, Wang Q, Li Z, Ma X, Wu L, Ji H, Qin G.
    J Exp Clin Cancer Res; 2015 Dec 04; 34():146. PubMed ID: 26637328
    [Abstract] [Full Text] [Related]

  • 5. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
    Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, Criscimanna A, Di Blasi F, Pitrone M, Zerilli M, Amato MC, Spinelli G, Carina V, Modica G, Latteri MA, Galluzzo A, Giordano C.
    Endocr Relat Cancer; 2011 Dec 04; 18(6):669-85. PubMed ID: 21903858
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-κB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia.
    Zhou D, Li Z, Bai X.
    Med Sci Monit; 2018 Sep 26; 24():6795-6808. PubMed ID: 30254191
    [Abstract] [Full Text] [Related]

  • 9. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
    Buffet C, Hecale-Perlemoine K, Bricaire L, Dumont F, Baudry C, Tissier F, Bertherat J, Cochand-Priollet B, Raffin-Sanson ML, Cormier F, Groussin L.
    PLoS One; 2017 Sep 26; 12(9):e0184861. PubMed ID: 28910386
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [The correlation between BRAF mutations, RET/PTC rearrangements and platelet-derived growth factor B expression in papillary thyroid carcinomas].
    Wang P, Wang YG, Zhao WJ, Fu YD, Wang L, Wang F, Zhao SH.
    Zhonghua Nei Ke Za Zhi; 2012 Dec 26; 51(12):987-91. PubMed ID: 23327964
    [Abstract] [Full Text] [Related]

  • 13. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 14. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
    Rumiantsev PO, Zaletaev DV, Vasil'ev EV, Saenko VA, Il'in AA, Rumiantseva UV, Abrosimov AIu, Medvedev VS.
    Vopr Onkol; 2006 Mar 15; 52(2):145-9. PubMed ID: 17195637
    [Abstract] [Full Text] [Related]

  • 15. 5'-AMP-Activated Protein Kinase Regulates Papillary (TPC-1 and BCPAP) Thyroid Cancer Cell Survival, Migration, Invasion, and Epithelial-to-Mesenchymal Transition.
    Cazarin JM, Coelho RG, Hecht F, Andrade BM, Carvalho DP.
    Thyroid; 2016 Jul 15; 26(7):933-42. PubMed ID: 27121619
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC, Fredrick MJ, Clayman GL.
    Arch Otolaryngol Head Neck Surg; 2007 Aug 15; 133(8):810-5. PubMed ID: 17709622
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.